



By late fall 2010, the University of Saskatchewan (U of S) will be home to the \$140-million International Vaccine Centre (InterVac), one of the largest Containment Level 3 (CL3) vaccine research and development facilities in North America. InterVac will be located at the Vaccine and Infectious Disease Organization (VIDO).

## > A MESSAGE TO OUR PARTNERS IN ACADEMIA:

*“Part of the Vaccine and Infectious Disease Organization (VIDO), InterVac will be a key player in Canada’s vaccine preparedness strategy. Working together, VIDO and InterVac will reshape the landscape for infectious disease research in Canada, secure Saskatchewan’s international leadership in vaccine development, and provide unparalleled research, teaching and graduate study opportunities.*

*“VIDO-InterVac will attract researchers from around the world. Students and postgraduates in areas such as veterinary medicine, medicine, engineering, toxicology and vaccinology will benefit greatly from the valuable training InterVac will provide and the doors to exciting future opportunities that will be opened as a result of working at VIDO-InterVac.”*

– Dr. Andrew Potter, Director, VIDO-InterVac

### VIDO-InterVac

VIDO has been in operation at the University of Saskatchewan since 1975. InterVac will build on VIDO’s experience, provide exceptional facilities, and quality collaborative science. VIDO-InterVac will continue to build the University of Saskatchewan’s reputation for excellence in the study of infectious disease and vaccine research, positioning Canada as a global leader.

Some VIDO highlights:

- VIDO is competitive nationally and internationally, with more than 80 awarded U.S. patents.
- VIDO has commercialized eight vaccines, six of which were world firsts.

- VIDO employs more than 150 people, and is the headquarters of the Pan-Provincial Vaccine Enterprise (PREVENT), one of Canada’s new Centres of Excellence in commercialization and research.
- VIDO is a non-profit entity working to accelerate the rate at which vaccines are available to the public.
- VIDO has received millions of research dollars from organizations such as the Gates and Krembil Foundations and agencies such as the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, Genome Canada, National Institutes of Health, and others.

“Research centres like VIDO-InterVac are placing the U of S among the leading universities in the country. InterVac, the Canadian Light Source, and our unique array of life science programs are establishing a global reputation for the University of Saskatchewan, attracting top faculty and students to the campus.”

President Peter MacKinnon  
University of Saskatchewan

## Life Sciences Research Cluster

VIDO-InterVac is part of the dynamic research and bioscience cluster that exists on the University of Saskatchewan campus and includes:

- Colleges of medicine, nursing, pharmacy and nutrition, the Western College of Veterinary Medicine, and the School of Public Health;
- The University's research park, Innovation Place, one of the most successful in North America in developing new ideas in fields ranging from agricultural biotechnology and pharmaceutical development, to advanced communications and information technology; and
- The Canadian Light Source, the country's only synchrotron.

## Opportunity

VIDO-InterVac will be a world leader in the development and delivery of vaccines. The physical design of the facility and its multi-disciplinary team of scientists and support staff will create opportunities for collaboration, and allow both researchers and industry to work together effectively to develop and test vaccines that will benefit people around the world.

## The biggest and best

The \$140-million VIDO-InterVac will be one of the largest Containment Level 3 (CL3) vaccine research and development facilities in North America. InterVac's large space and distinctive design will allow for a range of experimental designs from pre-clinical testing to licensing trials.

## Where great minds meet

A defining feature of VIDO-InterVac is its status as an accessible facility suitable for CL3 infectious disease research and development. VIDO-InterVac will be open to academic teams, commercial partners, researchers from Canadian and international universities, research institutes and governments.

## Focus on animal and human health

VIDO-InterVac is unique in its ability to focus on diseases that impact both humans and animals, as well as those diseases that can have significant economic consequences. Some examples of CL3 diseases that can be examined at VIDO-InterVac include:

- Tuberculosis
- Influenza (including swine and avian influenza)
- Hantavirus
- HIV
- BSE (Mad Cow disease)
- Chronic wasting disease
- Creutzfeldt-Jakob Disease
- SARS
- Rabies
- West Nile virus
- Hepatitis C

## First responders

VIDO-InterVac will enable researchers to gain deeper understanding of CL3 infectious diseases and respond faster to emerging diseases affecting animals and humans. This will help commercial partners such as pharmaceutical companies bring their products to market faster, helping Canadians and people worldwide.



For more information about VIDO or InterVac, please visit [www.vido.org](http://www.vido.org) or contact us at:

### VIDO-InterVac

120 Veterinary Road, Saskatoon, SK S7N 5E3  
Phone (306) 966-7465 Fax (306) 966-7478

